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Abstract
Background: Serum IGF-I and IGF-II levels decline with age. IGF-I replacement therapy reduces the impact of age
in rats. We have recently reported that IGF-II is able to act, in part, as an analogous of IGF-I in aging rats reducing
oxidative damage in brain and liver associated with a normalization of antioxidant enzyme activities. Since
mitochondria seem to be the most important cellular target of IGF-I, the aim of this work was to investigate
whether the cytoprotective actions of IGF-II therapy are mediated by mitochondrial protection.
Methods: Three groups of rats were included in the experimental protocol young controls (17 weeks old);
untreated old rats (103 weeks old); and aging rats (103 weeks old) treated with IGF-II (2 μg/100 g body weight and
day) for 30 days.
Results: Compared with young controls, untreated old rats showed an increase of oxidative damage in isolated
mitochondria with a dysfunction characterized by: reduction of mitochondrial membrane potential (MMP) and ATP
synthesis and increase of intramitochondrial free radicals production and proton leak rates. In addition, in untreated
old rats mitochondrial respiration was not blocked by atractyloside. In accordance, old rats showed an
overexpression of the active fragment of caspases 3 and 9 in liver homogenates. IGF-II therapy corrected all of
these parameters of mitochondrial dysfunction and reduced activation of caspases.
Conclusions: The cytoprotective effects of IGF-II are related to mitochondrial protection leading to increased ATP
production reducing free radical generation, oxidative damage and apoptosis.
Background
The reduced activity of the GH-IGFs axis leads to a
condition known as the somatopause [1], which is char-
acterised by a decrease in lean body mass and an
increase in adipose mass, osteopenia, muscle atrophy,
reduced exercise tolerance and changes in the plasma
lipoprotein profile [2]. These alterations are similar to
those observed in younger adults with GH deficiency
[3]. Understanding that aging is an unrecognized condi-
tion of “IGF-I deficiency”, we have recently reported
that IGF-I replacement therapy restores many age-
related changes increasing testosterone levels and serum
total antioxidant capability and reducing oxidative
damage in brain and liver [4]. This cytoprotective (neu-
roprotective and hepatoprotective) activity of IGF-I in
aging rats is related to mechanisms of mitochondrial
protection including normalization of the potential
membrane and ATP synthesis and reduction of intrami-
tochondrial free radicals production [5].
More recently we have reported that IGF-II is able to
act, in part, as an analogous of IGF-I in aging rats indu-
cing neuroprotection and hepatoprotection without
increasing testosterone levels [6].
Mitochondria are specially sensitive to oxidative
damage in the pathogenesis of disease and aging [7,8].
Normal mitochondrial function is a critical place in
maintaining cellular homeostasis because mitochondria
produce ATP and they are the major intracellular source
of free radicals. Intracellular or extracellular insults con-
verge on mitochondria [9] and induce a sudden increase
in permeability of the inner mitochondrial membrane
the so-called mitochondrial membrane permeability
transition (MMPT). The MMPT is caused by the pores
opening in the inner mitochondrial membrane, dissipa-
tion of proton gradient, matrix swelling and outer
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initiate cell death because the pore opening lead to the
release of the mitochondrial cytochrome c activating the
apoptotic pathway of caspases.
One of the most sensitive points for the pore opening
is the adenosine nucleotide translocator (ANT) [10].
Since mitochondria are one of the most important cellu-
lar targets of IGF-I, the aim of this work was to investi-
gate if the cytoprotective properties of IGF-II therapy
are also related to mitochondrial protection.
Recently we have characterized the mitochondrial dys-
function in aging rats in a similar protocol [5]. In the
present work, the following parameters were studied:
mitochondrial membrane potential, intramitochondrial
Reactive Oxygen Species (ROS) production, ATP synth-
esis, oxygen consumption, proton leak rates, vulnerabil-
ity of pore opening and caspases activation [10-16] in
young controls, untreated old rats and old rats treated
with IGF-II, at low doses, for 30 days.
Materials and methods
Animals and experimental design
All experimental procedures were performed in compli-
ance with The Guiding Principles for Research Involving
Animals [17]. Healthy male Wistar rats, 17 weeks old
(wk), were used in this protocol as young controls
(group yCO, n = 6), and healthy male Wistar rats of 103
wk old were randomly assigned to receive either saline
(0.5 mL, group O, n = 6) or recombinant human IGF-II
(Lilly Laboratories, Madrid, Spain) subcutaneously (2 μg
IGF-II/100 g body weight and day in 0.5 mL of saline in
two divided doses, group O+IGF-II, n = 6) for 30 days.
Both food (standard semipurified diet for rodents; B.K.
Universal, Sant Vicent del Horts, Spain) and water were
given ad libitum. Rats were housed in cages placed in a
room with a 12-h light, 12-h dark cycle, and constant
humidity and temperature (20°C).
In the morning of the 31st day, rats were killed by
decapitation, and the liver was dissected. Fresh liver was
used to isolate mitochondria and to perform mitochon-
drial function tests using flow cytometry [4,11].
Samples were obtained simultaneously from young,
old-untreated rats, and old rats treated with IGF-II to
have paired data.
Isolation of liver mitochondria
Liver mitochondrial fraction was prepared according to
the method described by Schneider and Hogeboom with
modifications [12]. Liver samples were homogenized
(1:10 wt/vol) in an ice-cold isolation buffer containing
sucrose 0.25 M and 0.1% BSA buffered (pH 7.4) with
Tris-HCl 10 mM, and the isolation medium was identi-
cal without BSA or EDTA. The protein concentration
was measured using the Biuret method. The
homogenate was centrifuged at 800 × g for 10 min. The
resulting supernatant was centrifuged at 8,500 × g for
10 min. The supernatant was discarded, and the pellet
was diluted in cold isolation buffer and centrifuged at
8,500 × g for 10 min three times. The final mitochon-
dria pellet was resuspended in a minimal volume, and
aliquots were stored at -80°C until use in enzyme assays.
All procedures were conducted at 4°C.
Unless otherwise indicated, the standard incubation
medium had the following composition: 100 mM NaCl,
5 mM sodium-potassium phosphate buffer (pH 7.4), 10
mM Tris-HCl buffer (pH 7.4), and 10 mM MgCl2.
The respiratory substrates used were 5 mM potassium
glutamate plus 2.5 mM potassium malate and 5.0 mM
potassium succinate plus 4 μM rotenone.
Oxygen consumption
Oxygen consumption was measured using a Clark-type
electrode (Hansatech Instruments Ltd., using software
OXIGRAPH version 1.10; Norfolk, UK) in a 2 mL glass
chamber equipped with magnetic stirring.
The reaction was started by the addition of 6 mg
mitochondrial protein to 2 mL standard medium con-
taining rotenone 5 μM, oligomycin 1.3 mM, nigericin
100 pmol/mg protein, succinate 10 mM, ADP 200 μM,
and glutamate/malate 5/2.5 mM. Finally, it was stabi-
lized for 1 min at 30°C. Respiration rates are given in
nAtom-gram oxygen/mg·min. Phosphorylating respira-
tion (state 3) was initiated by addition of 200 nmol
ADP/mg protein. Phosphorylation efficiency (ADP/O
ratio) was calculated from the added amount of ADP
and total amount of oxygen consumed during state 3.
The state 4 is obtained with all substrates but ADP.
The ratio between state 3 rate and state 4 rate is
called the respiratory control ratio (RCR), and indicates
the tightness of the coupling between respiration and
phosphorylation. With isolated mitochondria the cou-
pling is not perfect, probably as a result of mechanical
damage during the isolation procedure. Typical RCR
values range from 3 to 10, varying with the substrate
and the quality of the preparation. Coupling is thought
to be better in vivo but may still not achieve 100%.
Flow cytometry analysis
Gated mitochondrial population was chosen by flow
cytometry, based on forward scatter and side scatter
within mitochondria samples, after obtaining one clear
mitochondria population.
Mitochondrial transmembrane electrical potential (MMP)
MMP (ΔΨ) was measured by the lipophilic cationic
fluorescent probe Rh-123 (Molecular Probes Inc.,
Eugene, OR), a fluorescent derivative of uncharged
dihydroRh-123, according to previous studies [4,5,12].
A mitochondrial suspension (50 μg/mL) was incubated
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uptake for 1 min at room temperature, and after add-
ing Rh-123 (260 nM) and incubating it for another
minute. After incubation, suspensions were immedi-
ately analyzed by flow cytometry. The values of the
fluorescence (FL) substrates were normalized to the
value obtained with the uncoupler carbonylcyamide-m-
chlorophenylhydrazone.
Rate of intramitochondrial reactive oxygen species (ROS)
generation
The rate of ROS generation from mitochondria was
measured after the formation of Rh-123 using the cyto-
metry method performed by O’Connor [12] with a small
modification. A mitochondrial suspension (100 μg/mL)
was incubated with 0.82 nM dihydro Rh-123 and 7 U/
mL horseradish peroxidase for 5 min at room tempera-
ture. The values of the FL substrates were normalized to
the value obtained without peroxidase and adding the
uncoupler CCCP. H2O2 (1 mM) was used with the posi-
tive control.
After incubation, the suspensions were immediately
analyzed. Gated mitochondrial population was chosen
by flow cytometry, based on forward scatter and side
scatter within mitochondria samples.
Cytofluorometric analysis was performed using a flow
cytometer EPICS XL (Beckman Coulter, Inc., Fullerton,
CA) equipped with a single 488 nm argon laser (15
mW). Green FL was detected with a wide-band filter for
Rh-123 centred in 525 ± 20 nm (FL1). A standard cyto-
gram based on the measurement of right angle scatter
vs. forward angle scatter was defined to eliminate cellu-
lar debris and aggregates. A minimum of 10,000 mito-
chondria per sample was acquired in list mode and
analyzed with System II version 3.0 Software (Beckman
Coulter).
Activities of mitochondrial complexes
Mitochondrial suspensions were thawed and diluted
with potassium phosphate. Activities of the respiratory
chain enzymes were measured at 37°C in Cobas Mira
(ABXMicro, Mannheim, Germany).
Measurements of cytochrome oxidase activity
Cytochrome oxidase activity was measured according to
the method described by Cortese et al.[ 1 6 ] .M i t o c h o n -
dria were resuspended in the medium containing (in
mM) 220 mannitol, 70 sucrose, 2.5 K2HPO4, 2.5 MgCl2,
and 0.5 EDTA. Antimycin A was then added to block
mitochondrial respiration through complex III. Reaction
was started by adding ascorbate/N, N, N’,N’-tetramethyl-
p-phenylenediamine as an electron donor.
Complex V, ATPase (EC 3.6.1.34.)
The activity was assayed by coupling the reaction to the
pyruvate kinase and lactate dehydrogenase systems, and
measuring reduced nicotinamide adenine dinucleotide
(NADH) oxidation at 340 nm. The assay system con-
tained Tris-HCl buffer 65 mM (pH 7.5), sucrose 300
mM, MgCl2 4.75 mM, ATP 4 mM, NADH 0.4 mM,
phosphoenolpyruvate 0.6 mM, potassium cyanide 5
mM, pyruvate kinase 700 U/mL, and lactate dehydro-
genase 1000 U/mL.
Assessment of “proton leak": the relationship between
respiration rate and MMP (ΔΨ)
Mitochondrial proton leak was calculated from respira-
tion rates and MMP expressing the ratio of protons for
each oxygen atom consumed [13-15]. The rate of proton
leak across the inner mitochondrial membrane is a func-
tion of the driving force (membrane potential) and
increases disproportionately with membrane potential.
Titration of membrane potential and state 4 oxygen
consumption by respiratory inhibitors were performed
simultaneously in separate vessels at 30°C. Nigericin was
added to collapse the pH difference across the mito-
chondrial inner membrane and, thus, ΔΨ had the value
of the proton motive force (Δp). Reactions were started
by the addition of 3 mg mitochondrial protein/mL stan-
dard medium containing also 3 mM rotenone, 1.3 mM
oligomycin, nigericin (100 pmol/mg protein), and 5 mM
succinate. The addition of inhibitors was begun when
the maximum value of the potential became stable (after
~2-3 min). When succinate was used as the substrate,
the titration was performed with malonate (K/salt) from
0-13 mM; at the end of each membrane potential trace,
the zero point was determined by addition of CCCP 1
mM. Rates of respiration during the titration with inhi-
bitors were measured with a Clark-type oxygen elec-
trode, and membrane potential with a flow cytometer
simultaneously with the measurements of membrane
potential.
Inhibition of Adenine Nucleotide Translocase (ANT) by
Atractyloside (Atr)
To establish the optimal concentration of Atr (Calbio-
chem-Novabiochem, San Diego, CA) needed for ANT
inhibition, the efficiency of Atr was first examined in its
classical role, i.e. for its ability to inhibit oxidative phos-
phorylation. For analysis, increasing Atr concentrations
(50-200 pmol/mg mitochondrial protein) were used
until complete inhibition of oxygen consumption was
obtained [9,18,19].
Oxidative damage and total antioxidant status (TAS) in
isolated mitochondria
Lipid hydroperoxides (LOOHs) were assessed in isolated
mitochondria as previously described by Arab and Ste-
ghens [20], and adapted for Cobas Mira (600 nm wave-
length) and mitochondria suspensions. Briefly, orange
xylenol (180 μL-167 μM) was added to 25 μL sample.
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of iron gluconate (45 μL-833 μM). LOOH was calcu-
lated using a standard curve of tert-butyl hydroperoxide,
and LOOH levels were expressed as nmol/mg mito-
chondrial protein. Intraassay and interassay coefficients
were 3 and 8%, respectively.
TAS, as total enzymatic and nonenzymatic antioxidant
capability, was evaluated in isolated mitochondria by a
colorimetric assay (Randox Laboratories Ltd., Ardmore,
Crumlin, UK) using the following principle: 2,2’-azino-di-
(’3-ethylbenzthiazoline sulfonate) was incubated with a
peroxidase (metmyoglobin) and H2O2 to produce the
radical cation 2,2’-azino-di-(’3-ethylbenzthiazoline sulfo-
nate)
·+. This has a relatively stable blue-green colour,
which is measured at 600 nm. Antioxidants in the added
sample cause suppression of this colour production to a
degree that is proportional to their concentration [21,22].
Assay for Caspase-3 and 9-Associated Activity
The cytoplasm and nuclear fractions were obtained by
cell fractionation. Briefly, tissue was disrupted and trea-
ted with lysis buffer (800 μL) containing 10 mM HEPES,
pH 7.9, 10 mM KCl, 0.1 mM ethylenediaminetetraacetic
acid (EDTA), 0.1 mM EGTA, 5 μg/mL aprotinin, 10 μg/
mL leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, 1
mM ditiothreitol (DTT), and 0.6% Nonidet NP-40 for
10 min on ice. Afterward, samples were homogenized
and centrifuged at 15,000 g for 3 min at 4 °C. Aliquots
of the supernatant (cytoplasm) were stored at -80 °C
until use for the measurement caspase-3 activation. The
pellet (nuclear fraction) was discarded. The caspase-3-
associated activity in the sample (25 μg) was measured
using N-acetyl-Asp-Glu-Val-Asp-7-amino-4-trifluoro-
methy coumarin (Ac-DEVD-AFC, Bachem AG, Buben-
dorf, Switzerland) (100 μM) in caspase-incubating buffer
(50 mM HEPES pH 7.5, 100 mM NaCl, 10% sucrose,
0.1% CHAPS, 1 mM EDTA, and 5 mM DTT) up to 100
μL of total volume. The fluorescence of the sample (Ex
= 400, and Em = 505) was recorded using a GENios
Microplate Reader (TECAN, Salzburg, Austria).
Statistical analysis
Data are expressed as means ± sem. Statistical signifi-
cance was estimated with the paired or unpaired t test
as appropriate. A P value lower than 0.05 was consid-
ered significant (*p < 0.05 vs yCO and
&p < 0.05 vs O).
All analyses were performed using the SPSS version 15.0
(SPSS, Inc., Chicago, IL) statistical package.
Results
The mitochondrial dysfunction in aging rats was
previously characterized [5] in isolated hepatic
mitochondria.
Effect of low doses of IGF-II on Mitochondrial Membrane
Potential (MMP)
The MMP, which is considered a good marker of mito-
chondrial function, was monitored by FL quenching of
Rh-123 in mitochondria from the livers of rats under
different conditions: the resting state 4 (with all sub-
strates but ADP); the active state 3 (with ADP); and
with oligomycin, which deactivates ATPase showing the
conditions of maximum intramitochondrial negativity.
Table 1 summarizes the MMP values, expressed as
arbitrary units (AU), in the three experimental groups,
when succinate was used as substrate. According to pre-
v i o u sd a t a[ 5 ] ,ar e d u c t i o no fM M Pw a so b s e r v e di n
untreated aging rats compared with young controls,
which IGF-II therapy was able to restore to similar
values to those found in young controls, as IGF-I repla-
cement therapy had reached [4,5]. No changes were
observed using glutamate/malate as substrates (see
Additional File 1, Table S1).
Mitochondrial oxygen consumption
Table 2 shows oxygen consumption under different con-
ditions and Respiratory Control Ratios (RCRs) in mito-
chondria from the three experimental groups, when
succinate was used as substrate. Untreated old rats (O
group) showed higher values of oxygen consumption
compared with young controls, but no significant differ-
ences were found between yCO and O+IGF-II groups.
Interestingly, mitochondria from old rats treated with
IGF-II expended significantly lower amounts of oxygen
compared with untreated old animals (P <0 . 0 5 )w i t ha
significantly better efficiency because MMP returned to
values similar to those found in young controls, whereas
O group showed a depletion of MMP as is described in
Table 1 and in a preliminary study [6]. However, when
glutamate/malate were used as substrates, no significant
changes were found (Suppl. Table 1).
In addition, the ratio ADP/Oxygen (ADP/O) expres-
sing oxidative phosphorylation as ATP produced by oxy-
gen molecule consumed, was significantly reduced in
mitochondria from O group (P< 0.05 vs.y C Oa n dO
+IGF-II groups), when either succinate (Table 2) or glu-
tamate/malate (Suppl. Table 1) were used as substrates,
whereas old rats treated with low doses of IGF-II
showed similar values to those found in young controls.
No significant differences were found among the three
experimental groups in RCRs (state 3 to state 4).
Proton leak rates
The rate of proton leak across the inner mitochondrial
membrane is a function of the driving force (membrane
potential) and increases disproportionately with mem-
brane potential [13,14]. Proton leak rates express “pro-
ton escape” into mitochondrial matrix contributing to
dissipation of the MMP in pathological conditions.
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experimental groups, expressed by oxygen consumption
(nAgO·mg
-1·min
-1)a tag i v e nM M Pi ns t a t e4( w i t h o u t
ADP). Mitochondria from untreated old rats needed to
consume more oxygen to reach the same MMP values
as compared to young controls. As Figure 1 express in
mitochondria from old animals treated with IGF-II the
“proton escape” was reduced suggesting a more effective
utilization of the oxygen leading to a suitable proton
gradient.
Intramitochondrial Reactive Oxygen Species (ROS)
production
Figure 2 shows the intramitochondrial ROS production
in isolated mitochondria from the three experimental
groups. Mitochondria from untreated aging rats showed
a significant increase of ROS generation compared with
mitochondria from young controls and O+IGF-II.
All these data prove an incorrect use of oxygen by
mitochondria from untreated old rats, which do not
a c h i e v et h es u i t a b l ep r o t o ng radient. Consequently the
MMP results insufficient for the activity of the ATP
synthase.
Activities of cytochrome oxidase and ATP synthase
complexes
Cytochrome oxidase activity (nAgO·mg
-1·min
-1)
expressed as oxygen consumption in this complex was
significantly reduced in O group compared with young
controls (yCO: 65.45 ± 3.90 vs.O :4 6 . 1 0±5 . 7 5 ;P
<0.05). However, no differences were found between
yCO group and old rats treated with IGF-II (O+IGF-II:
61.48 ± 7.10, P=not significant vs. yCO and P< 0.05 vs.
O group).
ATPase activity (expressed as μmol ATP produced per
molecule of Oxygen consumed) was significantly
reduced in untreated aging rats (O: 0.13 ± 0.01 vs yCO:
0.18 ± 0.01, P <0 . 0 5 ) .H o w e v e r ,t h e r ew e r en os i g n i f i -
cant differences between yCO and O+IGF-II groups in
complex V activity (O+IGF-II: 0.20 ± 0.02, P <0 . 0 5v s
O group), according to preliminary data [6].
Estimation of the vulnerability to pore opening by
Atractyloside (Atr)
Blockage of oxygen consumption by Atr
In physiological conditions Atr competes with ADP in
ANT blocking mitochondrial respiration. Full inhibition
of the oxygen consumption induced by addition of ADP
was obtained in liver mitochondria from young controls
at a concentration of 150 pmol/mg Atr: see Figure 3.
In this environment of increased intracellular ROS in
old rats, ANT can be oxidized [18,19], leading to an
eventually uncoupling of this transporter. In this condi-
tion, mitochondrial respiration becomes Atr insensitive.
Consistently with this hypothesis, our study show that
Atr did not inhibit respirati o ni nm i t o c h o n d r i af r o m
untreated aging rats (O group) (Figure 3). Interestingly,
Atr inhibition was close to young controls in mitochon-
dria from O+IGF-II showing a normal ANT coupling.
In this group (O+IGF-II) as shown in Figure 3, full
Table 1 Mitochondrial Membrane Potential (expressed as arbitrary units of fluorescence, AUF) in isolated liver
mitochondria from the three experimental groups, using succinate as substrate.
Young controls (yCO) (n = 6) Untreated old rats (O)
(n = 6)
Old rats treated with IGF-II O+IGF-II (n = 6)
Succinate (State 4) 191.90 ± 18.05 160.55 ± 16.15
a 188.60 ± 19.00
b
+ ADP (State 3) 133.95 ± 13.30 125.40 ± 17.10 131.40 ± 11.40
+ Oligomycin 217.55 ± 17.10 158.65 ± 17.10
a 223.85 ± 14.25
b
Values are mean ± SEM. P, ns yCO group vs. O+IGF-II group in all conditions.
a P < 0.05 vs yCO
b P < 0.05 vs O
Table 2 Oxygen consumption by mitochondria from the three experimental groups, using succinate as substrate.










88.35 ± 6.65 62.70 ± 5.70
a 74.00 ± 15.00
RCR 3.30 ± 0.80 3.10 ± 0.50 3.20 ± 0.90
ADP/Oxygen 1.71 ± 0.19 1.05 ± 0.28
a 2.01 ± 0.41
b
Values are mean ± SEM. ADP/Oxygen expresses oxidative phosphorylation: ATP produced by oxygen molecule consumed. RCR = Respiratory Control Ratio (ratio
State 3/State 4).
a P< 0.05 vs. yCO group
b P < 0.05 vs. O group
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concentration of 200 pmol/mg Atr.
Mitochondrial oxidative damage and Total Antioxidant
Status (TAS) in isolated liver mitochondria
Figure 4 shows intramitochondrial oxidative damage,
using lipid hydroperoxides (LOOHs) as markers [20-22],
and total antioxidant capability of isolated mitochondria
[21,22]. Mitochondria from untreated old rats showed
an increase in oxidative damage and a reduction in TAS
compared with young controls. IGF-II therapy was able
to improve both parameters.
Effect of IGF-II on caspase 3 and caspase 9 activity
Assays for caspase 3 associated activity showed a signifi-
cant increase of caspase 3 activation in untreated aging
rats compared with young controls (Figure 5). However, a
reduction in the expression of the active fragment of cas-
pase 3 was observed in old animals treated with IGF-II.
Caspase 9 showed the same pattern with an increased
activity in untreated aging rats compared with young
controls (Figure 5; P< 0.05). Again, IGF-II treatment
induced a significant reduction of the activity of caspase
9 proving a diminution of this apoptotic pathway.
Discussion
The impact of the reduced activity of GH/IGFs axis in
age-related changes is not fully understood. It has been
demonstrated that IGF-I replacement therapy reduces
the impact of age in rats [4,5], improving glucose and
lipid metabolisms, increasing testosterone levels and
serum total antioxidant capability and reducing oxida-
tive damage in brain and liver associated with a normal-
ization of antioxidant enzyme activities and
mitochondrial function.
These beneficial effects of IGF-I may have been due to
suppressing endogenous GH release. Current studies in
our laboratory are designed to prove this mechanism.
Figure 1 Proton leak curves expressed by oxygen consumption
(nAgO·mg
-1·min
-1) and Mitochondrial Membrane Potential
(MMP, in arbitrary units) in state 4 (without ADP). Proton leak
rates express proton “escape” into mitochondrial matrix contributing
to the dissipation of the MMP under pathological conditions.
Mitochondria from untreated aging rats needed to consume more
oxygen to reach the same value of MMP compared with young
controls and old rats treated with IGF-II.
Figure 2 Intramitochondrial H2O2 production in isolated
mitochondria from the three experimental groups.
Figure 3 Blockage of oxygen consumption by Atractyloside
(Atr). In normal conditions, Atr competes with ADP in ANT blocking
oxygen consumption. In this case, Atr was not able to block oxygen
consumption in mitochondria from untreated aging rats, suggesting
an uncoupling of the ANT probably caused by oxidation of ANT-
thiol groups [18,19]. In this condition of mitochondrial oxidative
damage, respiration is Atr insensitive.
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IGFs deficiency, more than GH, we have recently
reported that the exogenous administration of IGF-II
induces similar effects of IGF-I in aging rats, without
increasing testosterone levels [6]. Therefore, these data
allow us to confirm that the neuroprotective and hepa-
toprotective actions are owed to specific properties of
IGFs.
In this context, since mitochondria are one of the
most important cellular targets of IGF-I, the present
study analyzed the effects of IGF-II therapy on hepatic
mitochondria from old animals.
Results in this paper showed that mitochondrial dys-
function leading to apoptosis (by caspase activation) was
normalized by IGF-II therapy, at low doses. In fact, IGF-
II treatment during 30 days recovered mitochondrial
oxidative damage, mitochondrial proton gradient (result-
ing in an increase of MMP) and ATP synthesis and
reduced free radical generation by mitochondria, proton
leak rate and the vulnerability for pore opening in ANT
which was associated to a reduction of caspase activa-
tion compared with untreated old rats.
We had previously characterized mitochondrial dys-
function in aging rats [5]. The observed reduction of
MMP with an increased generation of H2O2 suggests
that oxygen is wasted by damaged mitochondria produ-
cing ROS instead of a normal proton gradient that is
the driving force of ATP synthase [14]. IGF-II therapy
was able to reduce mitochondrial membrane damage
and restore all parameters of mitochondrial function as
IGF-I replacement therapy.
Together, these data suggest an extramitochondrial
protection of mitochondria by IGFs, which is not fully
established. Previously, we reported that low doses of
IGF-I restored the expression of the serine protease
inhibitor 2 (a1- antichymiotripsinogen) in cirrhotic rats
[23], which could contribute to the outlined mitochon-
drial protection. In agreement with the results in this
paper, it has been reported that IGF-I and II have antia-
poptotic properties [24-27].
The main finding in this work was that IGF-II at low
d o s e sa c t sa sa na n a l o g o u so fI G F - Ii n d u c i n gc e l lr e s i s -
tance to apoptosis by oxidative stress through mitochon-
drial protection leaded to ATP production. IGF-II
therapy resulted -as IGF-I replacement therapy- in an
increment of ATP synthesis. Interestingly, several bene-
ficial effects of IGF-II in aging [6] could be related to an
increased ATP availability similar to those described for
IGF-I therapy [4,5], in accordance with Sonntag WE et
al [28]. This mechanism could explain, at least in part, a
significant amount of evidence that have been accumu-
lated during the last years indicating that IGF-I and
Figure 5 Assays for caspases 3 and 9 associated activity.
Figure 4 Lipid oxidative damage and Total Antioxidant Status (TAS) in isolated mitochondria from the three experimental groups.
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factors [29-35], and more recently the reported action of
IGF-II administration in the enhancing memory reten-
tion and preventing forgetting [36], suggesting this hor-
mone as a possible novel target for cognitive
enhancement therapies.
Another point that deserves particular mention is that
IGF-II treatment improved significantly lipid metabo-
lism, diminishing cholesterol and triglycerides and
increasing free fatty acids circulating levels [6]. Since
fatty acids are synthesized at mitochondria, this result is
consistent with both the mentioned normalization of
mitochondrial function, and previously reported findings
by Liang G and col. [32].
Conclusion
In conclusion, results in this paper reinforce seriously
this concept: aging is mainly a condition of IGFs defi-
ciency, in which mitochondrial dysfunction is one of the
most relevant endpoint as an intracellular source of free
radicals perpetuating oxidative cellular damage and
causing ATP depletion. This work provides new evi-
dence regarding the impact of IGFs declination in aging,
clearly suggesting a strong clinical relevance since IGF-
II therapy reduces age-related side effects in rats without
increasing testosterone levels, potentetially worsening
diseases such as prostate hypertrophy or neoplasia.
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